INCY - Incyte Corporation
Chart Events
Momentum
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 107.87 |
| Open | 107.74 |
| Bid | 103.00 x 800 |
| Ask | 108.40 x 900 |
| Day's Range | 104.54 - 108.17 |
| 52 Week Range | 62.48 - 110.37 |
| Volume | 794,631 |
| Avg. Volume | 1,669,923 |
| Market Cap | 22.772B |
| Beta (5Y Monthly) | 1.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.75 |
| Earnings Date | Jul 28, 2020 - Aug 03, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 102.07 |
Fair Value
Related Research
- Motley Fool
Here's Why Incyte Rose 19.1% in the First Half of 2020
Shares of Incyte (NASDAQ: INCY) rose more than 19% in the first six months of the year, according to data provided by S&P Global Market Intelligence. After struggling to commercialize pipeline assets in recent years and diversify revenue away from Jakafi, Incyte appears to be making tangible progress with its late-stage pipeline. Wall Street appears a little more willing to buy into the company's growth pitch, which rests on a solid foundation provided by the Jakafi franchise.
- Insider Monkey
Were Hedge Funds Right About Incyte Corporation (INCY)?
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]
- Investor's Business Daily
These 3 Biotech Stocks Are Outperforming Their Peers — Here's Why
The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth.
- Business Wire
Incyte Announces Approval of Tabrectaâ„¢ (capmatinib) in Japan for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with METex14
Incyte Announces Approval of Tabrectaâ„¢ (capmatinib) in Japan for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with METex14
- Zacks
Gilead's (GILD) Remdesivir Gets CHMP Approval Recommendation
Gilead's (GILD) experimental coronavirus drug, remdesivir, has been recommended for approval by the EMA's human medicines committee.
- Zacks
Gilead to Start Studies for an Inhaled Version of Remdesivir
Gilead (GILD) announces plans to start studies for an inhaled version of the experimental candidate, remdesivir, in August.
- Zacks
Nasdaq's Excels in Weekly Performance: 5 Best Stocks in ETF
In a tug of war between bulls and bears, the Dow Jones and S&P 500 gained at least 1% each last week while the Nasdaq Composite Index advanced over 3%.
- Zacks
Nasdaq Continues to Excel : 5 Best Stocks in ETF
In a tug of war between bulls and bears, the Dow Jones and S&P 500 gained at least 1% each last week while the Nasdaq Composite Index advanced over 3%.
- MarketWatch
Gilead's stock falls as it announces clinical trial for inhaled remdesivir
Shares of Gilead Sciences Inc. were down 1.2% in trading on Monday after the drugmaker said it plans to start Phase 1 clinical trials for an inhaled version of remdesivir, its treatment for severely ill COVID-19 patients. An intravenous version of the drug received an emergency use authorization from the Food and Drug Administration in May. The new study will first test this version of the investigational medication in healthy patients before moving on to COVID-19 patients. It is thought that an inhaled drug would be easier to administer outside of a hospital setting. "That could have significant implications in helping to stem the tide of the pandemic," CEO Daniel O'Day said in a letter on Monday. O'Day also said Gilead plans to test whether remdesivir can help patients before they become severely ill, in vulnerable patient populations like children and pregnant women, and in combination with other therapies, including Eli Lilly & Co. and Incyte Corp.'s Olumiant and Roche Holdings' Actemra. "We have been keen to explore how remdesivir might work when combined with anti-inflammatory agents, particularly in the most severely ill patients," he wrote. Gilead's stock is up 17.9% year-to-date, while the S&P 500 is down 4.1%.
- Zacks
Incyte (INCY) Looks Good: Stock Adds 8.3% in Session
Incyte (INCY) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
- MarketWatch
Coronavirus update: U.S. death toll tops 115,000 amid growing worry about uptick in cases in Florida, Texas among others
The U.S. death toll from the coronavirus illness COVID-19 climbed above 115,000 on Monday, and the stock market tanked amid growing concerns about the uptick in cases in several states after their first efforts to reopen after lockdowns.
- Barrons.com
Lilly Is Testing Its Arthritis Drug as a Coronavirus Treatment
The company said it is sponsoring a 400-patient randomized trial to confirm whether the drug Olumiant can moderate Covid symptoms.
- Business Wire
Incyte Launches New Global Responsibility Section on Incyte.com
Incyte Launches New Global Responsibility Section on Incyte.com
- MarketWatch
Lilly's shares drop as it enrolls first patient in COVID-19 study for arthritis drug
Shares of Eli Lilly & Co. were down 1.1% in premarket trading on Monday after the drugmaker said the first patient had been enrolled in a late-stage trial assessing rheumatoid arthritis drug Olumiant as a treatment for COVID-19. Olumiant, which was developed by Incyte Corp. and is licensed by Lilly, generated $426.9 million in revenue for Lilly in 2019. Several drugs developed to treat rheumatoid arthritis have become clinical targets in the hunt for COVID-19 treatments. This includes Olumiant, Roche Holdings' Actemra, and Regeneron Pharmaceuticals Inc. [: regn] and Sanofi 's Kevzara. The Phase 3 randomized, controlled clinical trial is testing Olumiant in hospitalized COVID-19 patients; it's expected to enroll 400 participants in the U.S., Europe, and Latin America, with an aim of reducing the cytokine storms that present in some of these patients. The National Institutes of Health is also conducting a trial evaluating Olumiant in combination with Gilead Sciences Inc.'s remdesivir. Lilly's stock has gained 9.2% year-to-date, while the S&P 500 is down 5.8%.
- Yahoo Finance Video
MARKETS: YF Premium Investment Idea: Incyte Corporation (INCY)
Yahoo Finance's Jared Blikre breaks down some of the features of the Yahoo Finance Premium package.
- Insider Monkey
Hedge Funds Souring On Incyte Corporation (INCY)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
- Zacks
Why Is Incyte (INCY) Up 2.9% Since Last Earnings Report?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire
Incyte to Present at Upcoming Investor Conferences
Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June:
- Business Wire
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings
- Zacks
Incyte, MorphoSys Application for Lymphoma Drug Validated
Incyte (INCY) and partner MorphoSys' application for tafasitamab gets validation by EMA.
- Business Wire
Incyte to Present at Upcoming Investor Conference
Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference (held virtually) on Tuesday, June 9, 2020 at 8:00 a.m. ET.
- ACCESSWIRE
MorphoSys and Incyte Announce the Validation of the European Marketing Authorization Application for Tafasitamab
MUNICH, GERMANY / ACCESSWIRE / May 20, 2020 / MorphoSys AG (MOR.F) Prime Standard Segment; MDAX & TecDAX; (MOR) and Incyte (INCY) today announced the validation of the European Marketing Authorization Application (MAA) for tafasitamab, an anti-CD19 antibody. The application seeks approval of tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), including DLBCL arising from low grade lymphoma, who are not candidates for autologous stem cell transplantation (ASCT).
- Business Wire
Incyte and MorphoSys Announce the Validation of the European Marketing Authorization Application for Tafasitamab
Incyte and MorphoSys Announce the Validation of the European Marketing Authorization Application for Tafasitamab
- Zacks
Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More
The biotech sector remains in focus with pipeline updates on coronavirus treatments.
